C12N 2760/10061
Methods of inactivation or attenuation
C12N2760/10061 (Methods of inactivation or attenuation) appears on 13 US grants and 19 published applications in this corpus.
Search patents in C12N- Granted patents
- 13
- Published applications
- 19
- Assignees
- 8
- Inventors
- 36
- Latest grant
- 18 Feb 2025
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 0 |
| 2010 | 0 | 1 |
| 2011 | 0 | 0 |
| 2012 | 1 | 0 |
| 2013 | 1 | 1 |
| 2014 | 1 | 2 |
| 2015 | 0 | 0 |
| 2016 | 1 | 2 |
| 2017 | 0 | 1 |
| 2018 | 3 | 1 |
| 2019 | 0 | 1 |
| 2020 | 3 | 0 |
| 2021 | 0 | 3 |
| 2022 | 1 | 1 |
| 2023 | 1 | 0 |
| 2024 | 0 | 1 |
| 2025 | 1 | 4 |
By publication year.
Subgroups
Granted patents
Recent patents
- Replication-defective arenavirus vectors18 Feb 2025US 12,227,755 B2UniversitäT ZüRich
- Immunogenic composition comprising a recombinant attenuated mopeia virus with a modified nucleoprotein displaying reduced exonuclease activity2 May 2023US 11,638,751 B2Institut Pasteur
- Replication-defective arenavirus vectors2 Aug 2022US 11,401,528 B2UniversitäT ZüRich
- Recombinant attenuated Mopeia virus comprising a modified nucleoprotein with reduced exonuclease activity1 Dec 2020US 10,849,969 B2Institut Pasteur
- Tri-segmented arenaviruses as vaccine vectors28 Jul 2020US 10,722,564 B2Universite De Geneve
- Replication-defective arenavirus vectors4 Dec 2025US 2025/0369015 A1UniversitäT ZüRich
- Multivalent mopevac-based immunogenic composition for vaccination against new world arenaviruses and therapeutic use(s) thereof3 Jul 2025US 2025/0213670 A1
- Live attenuated junin virus and related compositions and methods3 Jul 2025US 2025/0213672 A1Utah State University
- Modified arenavirus particles expressing mutant kras, mutated cancer driver gene, or tumor-associated antigen as cancer immunotherapies6 Mar 2025US 2025/0073324 A1Hookipa Biotech GmbH
- Tri-segmented arenaviruses as vaccine vectors14 Mar 2024US 2024/0082376 A1Universite De Geneve
Most cited
By later US patents
- Replication-defective arenavirus vectors17US 8,592,205 B2UniversitäT ZüRich · 2013
- Replication-defective arenavirus vectors13US 9,309,289 B2UniversitäT ZüRich · 2016
- Replication-defective arenavirus vectors11US 9,944,952 B2UniversitäT ZüRich · 2018
- Inactivating pathogens with oxidizing agents for vaccine production8US 8,124,397 B2Oregon Health & Science University · 2012
- Tri-segmented arenaviruses as vaccine vectors7US 10,722,564 B2Universite De Geneve · 2020